Table 5 Analysis of progression-free survival as per investigator review using Kaplan−Meier method (FAS − expansion phase)
Alpelisib 350 mg + Imatinib (N = 35) | |
|---|---|
Number of events, n (%) | 29 (82.9) |
Progression | 24 (68.6) |
Death | 5 (14.3) |
Number of censoring | 6 (17.1) |
Median PFS time (months), (95% CI) | 2 months (1.8, 4.6) |